Get the Daily Brief

All action, no filler. BioBriefs delivers biotech’s 10 must-know updates, every morning.

Latest Biotech News

COVID-19 Vaccine Policy and Public Health Controversy

September 18, 2025

US health officials face scrutiny amid planned changes to COVID-19 vaccine recommendations and childhood immunization schedules spearheaded by Health Secretary Robert F. Kennedy Jr. Former CDC...

Roche Boosts Metabolic Disease Portfolio with $3.5B 89bio Acquisition

September 18, 2025

Roche has agreed to acquire 89bio for up to $3.5 billion, marking its first deal of the year and a significant investment in the metabolic dysfunction-associated steatohepatitis (MASH) space. The...

Pfizer and Arvinas Exit PROTAC Development Following Clinical Setbacks

September 18, 2025

Pfizer and Arvinas have decided to out-license their lead program in the PROTAC collaboration after the candidate underperformed in late-stage trials. This pivot signifies a strategic withdrawal...

Breakthroughs in Genetic Editing: Safer Alternatives to CRISPR and Prime Editors

September 18, 2025

Researchers at University of California San Diego and Yale University have identified small nuclear RNA base editing as a safer alternative to the widely used CRISPR editing system, addressing...

VectorY and Shape Therapeutics Ink $1.2 Billion Gene Therapy Capsid Deal

September 18, 2025

VectorY Therapeutics has secured exclusive evaluation rights to Shape Therapeutics’ engineered AAV5-derived capsid, SHP-DB1, optimized for deep brain penetration in preclinical models. The...

Advances in Prostate Cancer Diagnostics with Noninvasive qPCR Assay

September 18, 2025

Precision oncology diagnostics firm NucleoBio and CLIA-certified PreCheck Health Services have entered a strategic collaboration to validate and process Prostac, a qPCR-based composite assay for...

Regeneron Advances Ultra-Rare Disease Treatment with FDA Filing Plans

September 18, 2025

Regeneron Pharmaceuticals reported that its experimental monoclonal antibody garetosmab achieved the primary endpoint in a Phase 3 trial for fibrodysplasia ossificans progressiva (FOP), an...

Novel Needle-Free Vaccine Delivery Achieved by Skin Stretching Technique

September 18, 2025

Researchers from INSERM and King's College London demonstrated that mechanically stretching mouse skin activates immune responses and transiently increases permeability without tissue damage,...

Eli Lilly’s Once-Monthly GLP-1 Pill Shows Advantage in Diabetes and Obesity Trials

September 18, 2025

Eli Lilly’s investigational GLP-1 receptor agonist orforglipron demonstrated superior blood sugar and weight loss outcomes compared to Novo Nordisk’s oral Rybelsus in a Phase 3 trial. The highest...

Controversy Surrounds US Vaccine Policy Amid CDC Leadership Changes

September 18, 2025

The US vaccine advisory process is under scrutiny as former CDC Director Susan Monarez testified that Health Secretary Robert F. Kennedy Jr. pressured her to approve vaccine recommendations...

Roche Acquires 89bio with $3.5B Deal to Access MASH Drug

September 18, 2025

Roche announced its acquisition of 89bio in a deal valued up to $3.5 billion, securing the rights to pegozafermin, an experimental treatment for metabolic dysfunction-associated steatohepatitis...

LB Pharmaceuticals Raises $285M in Nasdaq IPO, Plans Phase III Trial for Schizophrenia Drug

September 18, 2025

New York-based LB Pharmaceuticals successfully raised $285 million through an initial public offering on Nasdaq, marking a significant milestone in a challenging biotech funding environment. The...

CRISPR Advances Target Neurodevelopmental Disorder SCN2A Haploinsufficiency

September 18, 2025

Researchers have developed a novel CRISPR-based gene therapy approach aiming to treat SCN2A haploinsufficiency, a genetic cause of neurodevelopmental disorders including autism and epilepsy. The...

AI Designs Functional Bacteriophage Genomes to Combat Antibiotic Resistance

September 18, 2025

Scientists at Stanford University and the Arc Institute have leveraged advanced AI models to generate fully functional bacteriophage genomes, a first in the field. The study utilized a series of...

Regeneron’s Garetosmab Shows Efficacy in Rare Bone Disease Fibrodysplasia Ossificans Progressiva

September 18, 2025

Regeneron Pharmaceuticals reported positive Phase III results for garetosmab in fibrodysplasia ossificans progressiva (FOP), a rare disease causing abnormal bone formation. The drug significantly...

FDA Amplifies Enforcement on Pharmaceutical Advertising Compliance

September 18, 2025

The U.S. Food and Drug Administration has escalated its crackdown on misleading pharmaceutical and telehealth advertisements by releasing around 100 warning letters to firms including major...

GSK Pledges $30 Billion Investment for U.S. Manufacturing and R&D Expansion

September 18, 2025

GlaxoSmithKline announced comprehensive plans to invest $30 billion over five years to bolster U.S.-based drug manufacturing capabilities and research infrastructure. The initiative includes...

New AI Model Predicts Risks for Over 1,000 Diseases Simultaneously

September 18, 2025

Researchers have unveiled a powerful generative AI model trained on UK Biobank data capable of forecasting the risk and timing of developing more than 1,000 diseases up to a decade in advance....

Duke University Deploys New AI Tools to Enhance Clinical Care and Administrative Efficiency

September 18, 2025

Duke University Health System is implementing a strategic blend of proprietary and commercial artificial intelligence technologies designed to ease clinicians’ administrative burdens and improve...

Advancements in Kidney Disease Modeling with Complex Kidney Assembloids

September 18, 2025

Scientists from the University of Southern California have developed advanced kidney organoids termed assembloids that combine nephron and collecting duct structures, achieving unprecedented...